An antisense strategy to modulate estrogen receptor response (er.alpha. and/or er.beta.)
CA 2471127 A1 · Owner: Institut De Cardiologie De Montreal / Montreal Heart Institute · Inventors: Tanguay, Jean-Francois; Sirois, Martin
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides novel antisense oligonucleotides that target the genes and mRNAs encoding mammalian Estrogen Receptors (ER) alpha and/or beta and modulate the receptors' responses. These antisense oligonucleotides may be used alone or in combination with 17Beta estradiol or a related compound (genistein, estradiol derivatives...) to improve plaque stabilization, vascular healing and endothelial recovery after vascular injury. Also provided are methods for designing and testing the antisense oligonucleotides. Such oligonucleotides may be used to modulate the beneficial effects mediated by the ER on vascular healing for example, restenosis or , plaque stabilisation in …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 20, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 20, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 20, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.